Summary of opinion: Rybrevant, 25/04/2024 Positive
Submitted by Anonymous (not verified) on 26 April 2024 - 11:00
Summary of opinion: Rybrevant, 25/04/2024 Positive
SME Regulation and reports
Submitted by Anonymous (not verified) on 26 April 2024 - 10:24
SME Regulation and reports
Small and medium-sized enterprise (SME) office annual report 2023
Submitted by Anonymous (not verified) on 26 April 2024 - 10:18
Small and medium-sized enterprise (SME) office annual report 2023
Follow up EMA and EORTC multi-stakeholder workshop on soft tissue and bone sarcoma, Online, European Medicines Agency, Amsterdam, the Netherlands, 24 May 2024
Submitted by Anonymous (not verified) on 26 April 2024 - 10:14
Follow up EMA and EORTC multi-stakeholder workshop on soft tissue and bone sarcoma, Online, European Medicines Agency, Amsterdam, the Netherlands, 24 May 2024
Human medicines European public assessment report (EPAR): Spikevax (previously COVID-19 Vaccine Moderna), COVID-19 mRNA vaccine,elasomeran,elasomeran / imelasomeran,elasomeran / davesomeran,andusomeran, Date of authorisation: 06/01/2021, Revision: 45, Sta
Submitted by Anonymous (not verified) on 26 April 2024 - 8:49
Human medicines European public assessment report (EPAR): Spikevax (previously COVID-19 Vaccine Moderna), COVID-19 mRNA vaccine,elasomeran,elasomeran / imelasomeran,elasomeran / davesomeran,andusomeran, Date of authorisation: 06/01/2021, Revision: 45, Status: Authorised
Committee for Medicinal Products for Veterinary Use (CVMP): 12-14 March 2024, European Medicines Agency, Amsterdam, the Netherlands, from 12 March 2024 to 14 March 2024
Submitted by Anonymous (not verified) on 26 April 2024 - 8:21
Committee for Medicinal Products for Veterinary Use (CVMP): 12-14 March 2024, European Medicines Agency, Amsterdam, the Netherlands, from 12 March 2024 to 14 March 2024
Minutes of the CVMP meeting 12-13 March 2024
Submitted by Anonymous (not verified) on 26 April 2024 - 8:14
Minutes of the CVMP meeting 12-13 March 2024
Human medicines European public assessment report (EPAR): Xtandi, enzalutamide, Date of authorisation: 21/06/2013, Date of refusal: 26/04/2013, Revision: 23, Status: Authorised
Submitted by Anonymous (not verified) on 25 April 2024 - 16:12
Human medicines European public assessment report (EPAR): Xtandi, enzalutamide, Date of authorisation: 21/06/2013, Date of refusal: 26/04/2013, Revision: 23, Status: Authorised
Committee for Medicinal Products for Veterinary Use (CVMP): 16-18 April 2024, European Medicines Agency, Amsterdam, the Netherlands, from 16 April 2024 to 18 April 2024
Submitted by Anonymous (not verified) on 25 April 2024 - 16:09
Committee for Medicinal Products for Veterinary Use (CVMP): 16-18 April 2024, European Medicines Agency, Amsterdam, the Netherlands, from 16 April 2024 to 18 April 2024
Veterinary medicines European public assessment report (EPAR): Innovax-ND-H5, Turkey herpesvirus, strain HVT-ND-H5 (cell-associated), expressing fusion protein gene of Newcastle disease virus and haemagglutinin gene of Avian influenza virus subtype H5, St
Submitted by Anonymous (not verified) on 25 April 2024 - 15:36
Veterinary medicines European public assessment report (EPAR): Innovax-ND-H5, Turkey herpesvirus, strain HVT-ND-H5 (cell-associated), expressing fusion protein gene of Newcastle disease virus and haemagglutinin gene of Avian influenza virus subtype H5, Status: Opinion